肾炎康复片治疗原发性肾小球肾炎的多中心随机对照试验
这项多中心双盲随机对照试验纳入735例原发性肾小球肾炎患者,比较肾炎康复片与氯沙坦钾及联合用药的疗效。结果显示肾炎康复片可降低蛋白尿并改善中医证候积分,联合氯沙坦钾降蛋白尿优于单用氯沙坦钾,但未达15%优效阈值,eGFR等无显著变化,未见明显不良反应。
要点
- 肾炎康复片可降低原发性肾小球肾炎患者24小时蛋白尿并改善中医证候积分。
- 肾炎康复片联合氯沙坦钾降蛋白尿优于单用氯沙坦钾,但未达15%优效阈值。
- 治疗48周eGFR、血肌酐、血清白蛋白无统计学显著变化,未见明显不良反应。
核心结论
- 肾炎康复片可降低原发性肾小球肾炎患者蛋白尿并改善中医证候积分,eGFR下降速率无变化。
- 肾炎康复片联合氯沙坦钾降蛋白尿优于单用氯沙坦钾。
研究设计与样本
- 多中心、双盲、随机、对照临床试验,纳入18-70岁原发性肾小球肾炎患者735例。
- 患者来自中国19省41家医院,随机分为肾炎康复片、氯沙坦钾50mg或100mg、肾炎康复片联合氯沙坦钾50mg或100mg共五组。
- 纳入标准:血压≤140/90 mmHg,eGFR≥45 mL/min per 1.73 m2,24小时蛋白尿0.5-3.0 g。
- 主要结局为治疗48周后24小时蛋白尿水平变化。
主要发现
- 治疗48周,肾炎康复片组尿蛋白定量下降百分比较氯沙坦钾50mg组多8.78%±2.56%(P=0.006)。
- 氯沙坦钾50mg组尿蛋白定量下降百分比较氯沙坦钾100mg组少0.51%±2.54%(P=1.000)。
- 肾炎康复片联合氯沙坦钾50mg组较氯沙坦钾50mg组尿蛋白多降低13.39%±2.49%(P<0.001)。
- 肾炎康复片联合氯沙坦钾100mg组较氯沙坦钾100mg组尿蛋白多降低9.77%±2.52%(P=0.001)。
- 以15%为优效阈值,上述比较均无统计学显著性。
关键数值与推荐
- eGFR、血肌酐、血清白蛋白较基线无统计学显著变化。
- 服用肾炎康复片者中医证候积分平均变化-3.00[-6.00,-2.00],未服用者-2.00[-5.00,0],组间差异有统计学意义(P=0.003)。
- 各组均未见明显不良反应。
临床怎么用
- 原发性肾小球肾炎患者可考虑使用肾炎康复片以降低蛋白尿并改善中医证候积分。
- 肾炎康复片联合氯沙坦钾较单用氯沙坦钾进一步降低蛋白尿,但未达15%优效阈值,需结合临床个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease. OBJECTIVE: This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard drug, losartan potassium. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: This was a multicenter, double-blind, randomized, controlled clinical trial. Primary glomerulonephritis patients, aged 18-70 years, with blood pressure ≤ 140/90 mmHg, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min per 1.73 m2, and 24-hour proteinuria level of 0.5-3.0 g, were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups: SYKFT, losartan potassium 50 mg or 100 mg, SYKFT plus losartan potassium 50 mg or 100 mg. MAIN OUTCOME MEASURES: The primary outcome was change in the 24-hour proteinuria level, after 48 weeks of treatment. RESULTS: A total of 735 participants were enrolled. The percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78% ± 2.56% (P = 0.006) more than that in the losartan 50 mg group, which was 0.51% ± 2.54% (P = 1.000) less than that in the losartan 100 mg group. Compared with the losartan potassium 50 mg group, the SYKFT plus losartan potassium 50 mg group had a 13.39% ± 2.49% (P < 0.001) greater reduction in urine protein level. Compared with the losartan potassium 100 mg group, the SYKFT plus losartan potassium 100 mg group had a 9.77% ± 2.52% (P = 0.001) greater reduction in urine protein. With a superiority threshold of 15%, neither was statistically significant. eGFR, serum creatinine and serum albumin from the baseline did not change statistically significant. The average change in TCM syndrome score between the patients who took SYKFT (-3.00 [-6.00, -2.00]) and who did not take SYKFT (-2.00 [-5.00, 0]) was statistically significant (P = 0.003). No obvious adverse reactions were observed in any group. CONCLUSION: SYKFT decreased the proteinuria and improved the TCM syndrome scores of primary glomerulonephritis patients, with no change in the rate of decrease in the eGFR. SYKFT plus losartan potassium therapy decreased proteinuria more than losartan potassium therapy alone. TRIAL REGISTRATION NUMBER: NCT02063100 on ClinicalTrials.gov.
引用
- Wu J, Duan SW, Yang HT, et al. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. J Integr Med. 2021. PMID: 33589406. doi:10.1016/j.joim.2021.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。